Health Care Supplies

Assure Tech

Assure Tech released FY2026 Q1 earnings on April 29 Pre-Market (BJT), actual revenue CNY 71.2 M, actual EPS CNY -0.08

Assure Tech to Release FY2026 Q1 Earnings Report on April 30 Pre-Market BJT

Assure Tech to Release FY2025 Earnings on April 30 Pre-Market (BJT)

Assure Tech released FY2025 annual earnings on February 27 Pre-Market (BJT), actual revenue CNY 451.26 M, actual EPS CNY 0.55

Assure Tech released FY2025 Q4 earnings on February 27 Pre-Market (BJT), actual revenue CNY 125.97 M, actual EPS CNY 0.04

Assure Tech released FY2025 9 Months Earnings on October 30 During-Market (BJT), Actual Revenue CNY 325.29 M, Actual EPS CNY 0.5101

Assure Tech released FY2025 Q3 earnings on October 30 During-Market (BJT), actual revenue CNY 95.54 M, actual EPS CNY 0.04

Assure Tech to Release FY2025 Q3 Earnings on October 31 During-Market BJT

Assure Tech released FY2025 Semi-Annual Earnings on August 19 After-Market BJT, actual revenue CNY 229.75 M, actual EPS CNY 0.47

Assure Tech released FY2025 Q2 earnings on August 19 After-Market (BJT), actual revenue CNY 114.45 M, actual EPS CNY 0.2

Assure Tech to Release FY2025 Semi-Annual Earnings on August 20, 2025 (BJT)

Anxon Biotech Launches Chronic Disease Management App, Promoting Full-Cycle Services

Axbio Announces Decline in Revenue and Net Profit for Q1 2025

Assure Tech released FY2025 Q1 earnings on April 29 Pre-Market (BJT), actual revenue CNY 115.3 M, actual EPS CNY 0.27

Assure Tech FY2025 Q1 Earnings Release on April 30, Pre-Market BJT

Assure Tech FY2024 Annual Earnings Release on April 30, 2025 (BJT)

Anxu Bio Launches GluMate Chronic Disease Management App and Product Ecosystem in Hangzhou

Assure Tech released FY2024 Q4 earnings on February 27, 2025 (BJT) with actual revenue of CNY 137.43 M and EPS of CNY 0.4391

Assure Tech released FY2024 annual earnings on February 27, 2025 (BJT) with actual revenue of CNY 540.7 M and actual EPS of CNY 1.51

Anxu Biotech releases Q3 2024 report

The bleeding disorder testing market is projected to grow from USD 109.2 billion in 2025 to USD 234.6 billion by 2036, with a CAGR of 7.2%. This growth is driven by rising demand for performance-grade diagnostic solutions, increased hospital procurement, and a focus on regulatory compliance. Key segments include reagents and consumables, with hemophilia A being the leading indication. Major growth regions include China, India, Germany, France, and the United States, as healthcare institutions prioritize reliable diagnostic systems.

MorningStar

Siemens Healthineers AG

Roche

Thermo Fisher Scentific

Abbott Laboratories

Horiba , Ltd.

Pfizer

Baxter

ROCHE HOLDINGS AG

FMI Reveals Bleeding Disorder Testing Market USD 117.1 Billion in 2026 to USD 234.6 Billion by 2036 Driven by Expanding Demand for Performance-Grade Diagnostic Solutions

Chinese rehabilitation robot manufacturers are expanding into international markets, leveraging technological advancements despite facing regulatory challenges. Experts highlight the rapid development of robot technology and the importance of partnerships for market entry. The global rehabilitation equipment market is projected to grow significantly, driven by an aging population and increasing health issues. Companies are adapting their strategies to meet varying market receptiveness, particularly in Europe and the U.S.

Yicai

Chinese Rehab Robot Makers Leverage Tech Advantages to Expand Overseas, Experts Say

688075

300308

300476

300502

On October 20th, there were a total of 328 stocks in the A-share market with financing purchases exceeding 100 million yuan, with Zhongji Innolight leading at 4.746 billion yuan. VGT and Eoptolink ranked second and third with 2.824 billion yuan and 2.673 billion yuan, respectively. The stocks with financing purchase amounts accounting for over 30% of the total transaction amount on that day included Shuangyuan Technology, Anbang Guardian, and Assure Tech, with proportions of 39.54%, 36.83%, and 36.05%, respectively. There were 22 stocks with net financing purchases exceeding 100 million yuan, with Zhongji Innolight, VGT, and CATL ranking the top three at 1.124 billion yuan, 869 million yuan, and 503 million yuan, respectively

Zhitong

Zhongji Innolight

Eoptolink

328 stocks received over 100 million yuan in margin purchases, with Zhongji Innolight leading at 4.746 billion yuan

Assure Tech released its semi-annual report for 2025. During the reporting period, the company's operating revenue was 230 million yuan, a year-on-year decrease of 7.42%; the net profit attributable to the parent company was 59.3059 million yuan, a year-on-year decrease of 48.57%. The net profit after deducting non-recurring gains and losses was 23.5862 million yuan, a year-on-year increase of 24.85%. The basic earnings per share were 0.47 yuan

Assure Tech released its performance for the first half of the year, with a net profit attributable to the parent company of 59.3059 million yuan, a year-on-year decrease of 48.57%

On the evening of August 6th, Assure Tech announced that the company plans to use a portion of its temporarily idle self-owned funds not exceeding 4 billion yuan for cash management

Assure Tech: Plans to use no more than 4 billion yuan of temporarily idle self-owned funds for cash management

Assure Tech announced that its revenue for the first quarter of 2025 was 115 million yuan, a year-on-year decrease of 10.9%; net profit was 34.0296 million yuan, a year-on-year decrease of 51.52%

Assure Tech: Net profit in the first quarter of 2025 was 34.0296 million yuan, a year-on-year decrease of 51.52%

According to the Zhitong Finance APP, Assure Tech released its performance preliminary report for the year 2024. During the reporting period, the company achieved operating revenue of 555 million yuan, a year-on-year increase of 10.29%; the net profit attributable to the owners of the parent company was 201 million yuan, a year-on-year increase of 42.06%; the net profit attributable to the owners of the parent company after deducting non-recurring gains and losses was 35.3952 million yuan, a year-on-year decrease of 32.38%; basic earnings per share were 1.58 yuan/share

Assure Tech: Net profit for 2024 is 201 million yuan, a year-on-year increase of 42.06%

The "Global Cardiac Biomarkers Diagnostics Industry, 2024-2029" report highlights the industry's growth driven by rising cardiovascular disease prevalence and advancements in diagnostic technology. Key players include Roche Diagnostics and Abbott Rapid Diagnostics. The market is expected to grow significantly due to high-sensitivity assays, multiplex biomarkers, and increased POCT adoption. The Asia-Pacific region shows the fastest growth potential. The report covers lab-based and POCT testing methods, emphasizing the importance of early detection and comprehensive diagnostics in managing heart conditions.

GlobeNewswire

Global Cardiac Biomarkers Diagnostics Industry Research 2024-2029: Rising Prevalence of CVD and High Sensitivity POCT Driving Transformational Growth

300942

300760

Weilide Biomedical focuses on the in vitro diagnostic market and plans to auction 2,808 shares from February 4 to 6, with a starting price of 50 yuan, and is expected to be listed on February 24. The revenue for 2023 is 941 million yuan, with a net profit after tax of 152 million yuan. The revenue for 2024 is expected to be 991 million yuan, a year-on-year increase of 5.36%. The company emphasizes that in vitro testing and preventive medicine are important trends in global health management, and it will deepen the application of digital medical technology to promote stable growth in operations

money.udn.com

Bioeasy

Mindray

Huakang Clean

HAIER BIOMEDICAL

WHOLE SHINE MEDICAL

Skyray Instrument

YIDU TECH

Realcan

Weilider Biomedical focuses on in vitro diagnostics and will start bidding on the 4th, with an expected listing on the 24th

Assure Tech(688075.SH)